Updated Portfolio Breakdown (1 Week Later)
Trimmed a little off the top on some Rare Earth names and rotated the gains into more
$NOW.
$MNTS has completely supercharged the portfolio β up 152% this week alone π
Also opened a small position in
$TAOX as my only cryptoβlinked exposure via the treasury approach.
Hereβs how the SIPP looks now...
Total Portfolio:
Value: Β£82,530.95
Performance: ( 26.05%)
Holdings:
CoTech Holdings (5,263 shares)
$CTH.V β Β£4,194.61 (-8.09%)
Electra Battery Materials (2,833 shares)
$ELBM β Β£1,311.96 (-0.58%)
Greenland Energy (877 shares)
$GLND β Β£2,146.02 ( 8.59%)
Hims & Hers Health (276 shares)
$HIMS β Β£4,873.30 (-10.94%)
Moderna (223 shares)
$MRNA β Β£7,792.02 (-12.99%)
Momentus (2,500 shares)
$MNTS β Β£29,017.50 ( 172.15%)
MP Materials (125 shares)
$MP β Β£6,271.01 ( 3.52%)
Northrop Grumman (19 shares)
$NOC β Β£7,880.54 ( 0.35%)
ServiceNow (164 shares)
$NOW β Β£12,241.58 (-1.21%)
TAO Synergies (137 shares)
$TAOX β Β£459.55 (-4.50%)
USA Rare Earth (311 shares)
$USAR β Β£6,439.66 ( 12.19%)
Thoughts:
I probably hold too many names β ideally Iβd cap this at 6 β but right now diversification feels right given the asymmetric themes Iβm targeting.
Rare Earths, Space, SaaS revival, Defence, and undervalued Biotech all have huge upside potential in my view.
Moderna is a value play pandemic hedge. Hims remains one of my highestβconviction growth stories.
Greenland could explode if the narrative returns.
And CoTechβ¦ massively underβtheβradar but I think itβs worth far more longβterm.
Not bad for a week β and I donβt think weβve even started yet.
NFA. DYOR.
I'm all in now. No cash.
My portfolio is now built around 3 pillars:
1οΈβ£ AI & Enterprise Infrastructure
$NOW β the workflow brain of the Fortune 500. AI orchestration layer, not a hype stock.
2οΈβ£ U.S. National Security & Supply Chains
$MP,
$USAR,
$ELBM β the 2027 magnet ban means the U.S. must build domestic rareβearth capacity.
$NOC β defence exposure with real cash flow.
$CTH.NE /
$GLND β trimmed down to small speculative positions.
3οΈβ£ Asymmetric Growth
$HIMS β consumer health with real traction.
$MRNA β biotech platform optionality, pandemic hedge.
$MNTS β space infrastructure moonshot, SpaceX IPO sympathy move.
Macro thesis: AI defence U.S. reshoring strategic metals selective growth.